Werner Lanthaler

Dr. Werner Lanthaler was appointed Chief Executive Officer of Evotec AG in 2009. In his previous position, Dr. Lanthaler served as Chief Financial Officer of Intercell AG in Vienna, Austria, a global biopharmaceutical leader dedicated to the development of vaccines. In this role, he was also responsible for Business Development and Marketing & Sales.

Vishal Gulati

Dr. Vishal Gulati serves as a venture partner at Molten Ventures. Specialising in Digital Health, Dr. Gulati previously served at DFJ Esprit, Europe’s leading Silicon Valley style Venture Capital firm with over $1b under management. Since 2012, Vishal has been a leading promoter of investments into the emerging Digital Health sector and Chairman of Digital […]

Vincent Hennemand

Vincent Hennemand is the COO at Intergalactic Therapeutics. He was previously Senior Vice President of Strategy, Corporate & Business Development at Akili Interactive Labs. Prior to that he was a Principal in Sanofi’s corporate R&D venture group (“Sunrise”) where he was responsible for developing and managing new investment opportunities including Myokardia, Voyager Therapeutics, WarpDrive Bio, […]

Valentin Piëch

Dr. Valentin Piëch joined BioMed in 2015 with a background in venture capital, science, and technology. Dr. Piëch founded impact2partners AG, a private venture capital firm with a focus on companies developing treatments and diagnostics for rare diseases. Prior to impact2partners, he was Investment Analyst and then Principal at Nextech Invest, a venture capital firm […]

Regina Hodits

Regina Hodits is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of AYOXXA, Endostim, GTX Medical, Polares Medical, Themis, and TRiCares. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis/ Boston Scientific), and an external […]

Montse Vendrell

Montserrat Vendrell is partner at Alta Life Sciences since 2016. She sits in the board of Peptomyc, Accure Therapeutics (Chair), Ona Therapeutics and Inbrain Neuroelectronics (observer). Prior to Alta Life Sciences, Vendrell was founder and CEO of Biocat (Catalonia biocluster), and the Barcelona Science Park and its bioincubator. Vendrell also chairs the Executive Committee of […]

Lorenz Mayr

Dr. Mayr is the CEO of Vector BioPharma. Prior to Vector BioPharma, Dr. Mayr has been the Chief Technology Officer for GE Healthcare Life Sciences and was responsible for all R&D investments, research programmes, business growth strategy, technology innovation, and R&D talent development across all business areas (BioProcess, Imaging Diagnostics/Contrast Media, Research Tools and Applied […]

Jens Eckstein

Jens Eckstein has more than 15 years of venture capital experience in biopharma and 10 years of operational experience in drug discovery and development. Jens is a Kauffman Fellow and a mentor for life science entrepreneurs and start-up teams in the area of innovative life science and healthcare IT companies.

Ida Beerhalter

Ida Beerhalter is Co-head of IOME, a private investment office of women principals from the Persian Gulf with its head office in Riyadh, Kingdom of Saudi Arabia. She currently serves as Member of the Board of Auma Obama Foundation Sauti Kuu (Germany and Kenya), and is Head of Family Office Investments Division at Green Sands […]

Graziano Seghezzi

Graziano Seghezzi is Managing Partner at Sofinnova Partners which he joined in 2006. He seed funded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano also seed funded and is on […]